中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Inhibiting Endothelial Cell-Mediated T Lymphocyte Apoptosis with Integrin-Targeting Peptide-Drug Conjugate Filaments for Chemoimmunotherapy of Triple-Negative Breast Cancer

文献类型：期刊论文

作者Cai, Ying9,10,11; Zhu, Binyu9,10,11; Shan, Xiaoting9,10,11; Zhou, Lingli8; Sun, Xujie9,10,11; Xia, Anqi9,10,11; Wu, Binhao9,10,11; Yu, Yang7; Zhu, Helen He5,6; Zhang, Pengcheng3,4
刊名ADVANCED MATERIALS
出版日期2023-11-30
页码12
ISSN号0935-9648
关键词Fas ligand immunotherapy peptide-drug conjugate triple-negative breast cancer tumor-associated endothelial cells
DOI10.1002/adma.202306676
通讯作者Zhang, Pengcheng(zhangpch1@shanghaitech.edu.cn) ; Li, Yaping(ypli@simm.ac.cn)
英文摘要Tumor-associated endothelial cells (TECs) limit antitumor immunity via inducing apoptosis of infiltrating T lymphocytes through a Fas ligand (FasL) mediated mechanism. Herein, this work creates a peptide-drug conjugate (PDC) by linking 7-ethyl-10-hydroxycamptothecin (SN38) to hydrophilic segments with either RGDR or HKD motif at their C-terminus through a glutathione-responsive linker. The PDCs spontaneously assemble into filaments in aqueous solution. The PDC filaments containing 1% of SN38-RGDR (SN38-HKD/RGDR) effectively target triple-negative breast cancer (TNBC) cells and TECs with upregulated expression of integrin, and induce immunogenic cell death (ICD) of tumor cells and FasL downregulation of TECs. SN38-HKD/RGDR increases infiltration, activity, and viability of CD8+ T cells, and thus inhibits the growth of primary tumors and pulmonary metastasis. This study highlights the synergistic modulation of cancerous cells and TECs with integrin-targeting PDC filaments as a promising strategy for TNBC chemoimmunotherapy. SN38-HKD/RGDR nanofibers simultaneously induce immunogenic cell death of cancer cells and downregulate Fas ligand expression on tumor-associated endothelial cells (TECs). The treatment promotes antitumor immunity and reduces TEC-mediated T-cell apoptosis, significantly inhibiting the growth of primary TNBC tumors and pulmonary metastasis.image
WOS关键词ANGIOGENESIS ; NANOSTRUCTURES ; CHEMOTHERAPY ; EFFICACY ; VEGF
资助项目The National Key R&D Program of China ; Shanghai Advanced Research Institute, Chinese Academy of Sciences, China[2022YFC3401400] ; National Key R&D Program of China[32171374] ; National Key R&D Program of China[32130058] ; National Key R&D Program of China[22273107] ; National Natural Science Foundation of China[Y2021076] ; National Natural Science Foundation of China[153631KYSB20190013] ; Chinese Academy of Sciences[ZR2019ZD25] ; National Natural Science Foundation of Shandong Province
WOS研究方向Chemistry ; Science & Technology - Other Topics ; Materials Science ; Physics
语种英语
出版者WILEY-V C H VERLAG GMBH
WOS记录号WOS:001111341900001
源URL[http://119.78.100.183/handle/2S10ELR8/308149]  
专题新药研究国家重点实验室
通讯作者Zhang, Pengcheng; Li, Yaping
作者单位1.Yantai Inst Mat Med, Yantai Key Lab Nanomed & Adv Preparat, Yantai 264000, Shandong, Peoples R China
2.Bohai Rim Adv Res Inst Drug Discovery, Shandong Lab Yantai Drug Discovery, Yantai 264000, Shandong, Peoples R China
3.ShanghaiTech Univ, State Key Lab Adv Med Mat & Devices, Shanghai 201210, Peoples R China
4.ShanghaiTech Univ, Sch Biomed Engn, Shanghai 201210, Peoples R China
5.Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200127, Peoples R China
6.Shanghai Jiao Tong Univ, Renji Med X Stem Cell Res Ctr, State Key Lab Oncogenes & Related Genes, Sch Med,Dept Urol,Renji Hosp, Shanghai 200127, Peoples R China
7.Chinese Acad Sci, Shanghai Adv Res Inst, Natl Facil Prot Sci Shanghai, Shanghai 201210, Peoples R China
8.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China
9.Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China
10.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Pharmaceut, Shanghai 201203, Peoples R China
推荐引用方式
GB/T 7714		 Cai, Ying,Zhu, Binyu,Shan, Xiaoting,et al. Inhibiting Endothelial Cell-Mediated T Lymphocyte Apoptosis with Integrin-Targeting Peptide-Drug Conjugate Filaments for Chemoimmunotherapy of Triple-Negative Breast Cancer[J]. ADVANCED MATERIALS,2023:12.
APA Cai, Ying.,Zhu, Binyu.,Shan, Xiaoting.,Zhou, Lingli.,Sun, Xujie.,...&Li, Yaping.(2023).Inhibiting Endothelial Cell-Mediated T Lymphocyte Apoptosis with Integrin-Targeting Peptide-Drug Conjugate Filaments for Chemoimmunotherapy of Triple-Negative Breast Cancer.ADVANCED MATERIALS,12.
MLA Cai, Ying,et al."Inhibiting Endothelial Cell-Mediated T Lymphocyte Apoptosis with Integrin-Targeting Peptide-Drug Conjugate Filaments for Chemoimmunotherapy of Triple-Negative Breast Cancer".ADVANCED MATERIALS (2023):12.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。